Drug Discovery
By
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2 Billion Patients Worldwide?
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Can Cambridge and A*STAR’s New AI Digital Twin Platform Transform $50Bn Pharma Manufacturing Efficiency Landscape?
Key Takeaways AI-Driven Digital Twin for PharmaThe newly launched platform integrates AI with real-time plant data to create…
Can Amgen and Kyowa Kirin’s Rocatinlimab Redefine Atopic Dermatitis Care With Long-Term Safety and Sustained Efficacy in Over 2,600 Patients?
Key Insights: Breakthrough Data From ASCEND Long-Term Extension Amgen and Kyowa Kirin released top-line results from the global…
Lilly’s Jaypirca Shows Strong Phase 3 Results in Untreated CLL/SLL
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 BRUIN CLL-313 trial evaluating…
